TCI Peptide Therapeutics Overview
Update this profile
Latest Deal Amount
TCI Peptide Therapeutics General Information Description
Developer of therapeutics intended to help create drugs for the treatment of cachexia. The company's drugs are melanocortin based peptide drugs for treating cardiovascular problems which are free from any adverse cardiovascular side effects, enabling healthcare practitioners to use these drugs for proper treatment of cancer and other chronic diseases.
Want to dig into this profile?
We’ll help you find what you need
TCI Peptide Therapeutics Valuation & Funding
Raised to Date
4. Later Stage VC (Series A)
1. Early Stage VC
To view TCI Peptide Therapeutics’s complete valuation and funding history, request access »
TCI Peptide Therapeutics Signals
0.80%, 93rd %ile
219x, 100th %ile
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial